Last reviewed · How we verify
Nivolumab and Ipilimumab (nivolumab-and-ipilimumab)
Nivolumab and Ipilimumab (generic name: nivolumab-and-ipilimumab) is a Monoclonal antibody drug developed by Pfizer Inc.. It is currently FDA-approved.
Nivolumab and ipilimumab work by targeting PD-1 and CTLA-4 receptors, enhancing T-cell activation and immune response against cancer cells.
At a glance
| Generic name | nivolumab-and-ipilimumab |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | FDA-approved |
| Annual revenue | 2900 |
Mechanism of action
Nivolumab blocks the PD-1 receptor, while ipilimumab inhibits CTLA-4, both of which help to activate T-cells and boost the immune system's ability to fight cancer.
Approved indications
Common side effects
Key clinical trials
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (PHASE1)
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (PHASE1, PHASE2)
- A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nivolumab and Ipilimumab CI brief — competitive landscape report
- Nivolumab and Ipilimumab updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Nivolumab and Ipilimumab
What is Nivolumab and Ipilimumab?
How does Nivolumab and Ipilimumab work?
Who makes Nivolumab and Ipilimumab?
What is the generic name of Nivolumab and Ipilimumab?
What development phase is Nivolumab and Ipilimumab in?
What is Nivolumab and Ipilimumab's annual revenue?
Related
- Manufacturer: Pfizer Inc. — full pipeline
- Compare: Nivolumab and Ipilimumab vs similar drugs
- Pricing: Nivolumab and Ipilimumab cost, discount & access